In a more recent study, activated AXL was shown to associate with EGFR and HER3 in maintaining cell survival and inducing the emergence of EGFR-mutant NSCLC cells tolerant to osimertinib [92]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.